BoenS.T.Peritoneal dialysis in clinical medicine.Springfield: Charles C. Thomas, 1964.
2.
HendersonI.S., CouperlA, LumsdenA.Potentially irritant glucose metabolites in unused CAPD fluid. In: MaherJ.F., WinchesterJ.F., eds. Frontiers in peritoneal dialysis.New York: Field, Rich and Associates, 1986: 261–4.
3.
Personal communication from Baxter Healthcare Corporation, Deerfield, IL.
4.
DuweA.K., VasS.I., WeatherheadJ.W.Effect of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
5.
IngB.L., GuptaD.K., NawabZ.M., ZhouF.Q., RahmanM.A., DaugirdasJ.T.Suppression of neutrophil superoxide production by conventional peritoneal dialysis solution.Int J Artif Organs1988; 11: 351–4.
6.
YuA.W., VedereA.R., AgrawalA.Morphologic changes in human neutrophils after exposure to peritoneal dialysis solution (PDS) Abstract.J Am Soc Nephrol1991; 2: 370.
7.
TopleyN., AlobaidiH.M.M., DaviesM., ColesG.A., WilliamsJ.D., LloydD.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
8.
Van BronswijkH, VerbrughH.A., BosH.J.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
9.
ZhouX.J., YuA.W., IngT.S., VaziriN.D.Neutrophilic intracellular acidosis after exposure to peritoneal dialysis solution (PDS) containing lactate.Abstract J Am Soc Nephrol1991; 2: 370.
10.
SimehowitzL.Intracellular pH modulates the generation of superoxide radicals by human neutrophils.J Clin Invest1985; 76: 1079–89.
11.
TenckhoffH.Chronic peritoneal dialysis manual.Seattle: University of Washington School of Medicine, 1974.
12.
VaziriN.D., NessR., WelliksonL., BartonC., GreepN.Biarbonate-buffered peritoneal dialysis. An effective adjunct in the treatment of lactic acidosis.Am J Med1979; 67: 392–6.
VeechR.L.The toxic impact of parenteral solutions on the metabolism of cells: A hypothesis for physiological parenteral therapy.Am J Clin Nutr1986; 44: 519–51.
16.
FerianiM., BiasioliS., BorinD.Bicarbonate buffer for CAPD solution.Trans Am Soc Artif Intern Organs1985; 31: 668–72.
17.
YuA.W., ManahanF.J., FilkinsJ.P.Peritoneal dialysis using bicarbonate-containing solution sterilized by ultrafiltration.Int J Artif Organs1991; 14: 463–5.
18.
YatzidisH.A new stable bicarbonate dialysis solution for peritoneal dialysis: Preliminary report.Perit Dial Int1991; 11: 224–7.
19.
ManahanF.J., IngB.L., ChanJ.C.Effects of bicarbona tecontaining versus lacta te-containing peritoneal dialysis solutions on superoxide production by human neutrophils.Artif Organs1989; 13: 495–7.
20.
DaugirdasJ.T., lngT.S., GandhiV.C., HanoJ.E., ChenW.T., YuanL.Kinetics of peritoneal fluid absorption in patients with chronic renal failure.J Lab Clin Med1980; 95: 351–61.
21.
VasS.I., DuweA., WeatherheadJ.Natural defence mechanisms of the peritoneum: The effect of peritoneal dialysis fluid on polymorphonuclear cells. In: AtkinsR.C., ThomsonN.M., FarrellP.C., eds. Peritoneal dialysis.Edinburgh: Churchill Livingstone, 1981: 41–51.
22.
AhmedM.I., RawalP.A., PatelN.M.In vitro buffering capacity of residual peritoneal dialysate fluid: Implications for peritoneal dialysis.Artif Organs1992, in press.
23.
MooreA.L., GrantB.W., DorighiJ.A., BelinsonJ.L., StewartJ.A., AlbertiniR.J.Effect of commercial peritoneal dialysis fluids on the lytic function of Iymphokine activated killer cells.J Biol Response Mod1988; 7: 401–8.